Quotient Wealth Partners LLC Buys 226 Shares of AstraZeneca PLC (NASDAQ:AZN)

Quotient Wealth Partners LLC boosted its holdings in AstraZeneca PLC (NASDAQ:AZN) by 4.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,787 shares of the company’s stock after buying an additional 226 shares during the quarter. Quotient Wealth Partners LLC’s holdings in AstraZeneca were worth $451,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Cox Capital Mgt LLC acquired a new stake in AstraZeneca in the first quarter valued at about $2,683,000. TD Asset Management Inc boosted its stake in shares of AstraZeneca by 8.6% during the first quarter. TD Asset Management Inc now owns 1,537,410 shares of the company’s stock valued at $104,160,000 after purchasing an additional 121,876 shares in the last quarter. Northcape Wealth Management LLC acquired a new stake in shares of AstraZeneca during the second quarter valued at about $269,000. Wealthcare Advisory Partners LLC boosted its stake in shares of AstraZeneca by 9.7% during the first quarter. Wealthcare Advisory Partners LLC now owns 6,136 shares of the company’s stock valued at $416,000 after purchasing an additional 543 shares in the last quarter. Finally, Cetera Advisors LLC boosted its stake in shares of AstraZeneca by 124.5% during the first quarter. Cetera Advisors LLC now owns 98,262 shares of the company’s stock valued at $6,657,000 after purchasing an additional 54,488 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AZN. Citigroup raised AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Barclays upgraded AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Finally, TD Cowen raised their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Trading Down 0.8 %

Shares of AZN stock opened at $76.87 on Friday. The company has a market cap of $238.34 billion, a P/E ratio of 37.14, a PEG ratio of 1.43 and a beta of 0.46. The stock has a 50 day simple moving average of $81.45 and a two-hundred day simple moving average of $77.67. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.99 EPS for the quarter, beating the consensus estimate of $0.98 by $0.01. The firm had revenue of $12.45 billion during the quarter, compared to the consensus estimate of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The company’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.08 earnings per share. Research analysts forecast that AstraZeneca PLC will post 4.07 earnings per share for the current year.

AstraZeneca Cuts Dividend

The company also recently disclosed a Semi-Annual dividend, which was paid on Monday, September 9th. Stockholders of record on Friday, August 9th were issued a dividend of $0.49 per share. The ex-dividend date was Friday, August 9th. This represents a dividend yield of 1.8%. AstraZeneca’s dividend payout ratio is 47.34%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.